Neurodegenerative Diseases

Papers
(The TQCC of Neurodegenerative Diseases is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Publisher's Note35
The Immunomodulatory Potential Role of Mesenchymal Stem Cells in Diseases of the Central Nervous System13
Societal gender norms and their influence on Late Life Cognition8
Active immunization targeting amyloid β for the treatment of Alzheimer’s disease7
Sex Differences for Social Determinants Associated with Lewy Body Dementia Onset and Diagnosis7
A Review of Sex Differences in Neurodegeneration and Psychological Comorbidities in Multiple Sclerosis and Related Disorders6
Alzheimer’s Disease, β-Amyloid Peptides, and Ubiquitin-Proteasome System: Nutritherapeutic Insights6
The Impact of Drug Interactions on the Results of DAT-SPECT Imaging in a Specialty Movement Disorders Practice: A Retrospective Analysis of Outcomes6
A radiomics-based analysis of functional dopaminergic scintigraphic imaging for the diagnosis of dementia with Lewy bodies6
Contents Vol. 22, 20225
A Pivotal Time5
Front & Back Matter4
The genetic architecture of Parkinson's disease in Morocco: highlighting a predominance of Mendelian genes3
Age of Onset and Length of Survival of Queensland Patients with Amyotrophic Lateral Sclerosis: Details of Subjects with Early Onset and Subjects with Long Survival3
Subjective Sleep Disturbance and Lewy Pathology: Data from a Cohort of Essential Tremor Brain Donors3
Contents Vol. 23, 20232
Early Autonomic Symptoms Predict Functional Decline in Parkinson’s Disease Independent of Dopaminergic Therapy2
Fluid and waste clearance in central nervous system health and diseases2
Contents Vol. 24, 20242
XXXth Congress of Société Francophone Posture Equilibre et Locomotion, Paris, France, 5-6 December 2024 - Abstracts2
Front & Back Matter2
A Paradigm Shift in the Management of Patients with Parkinson’s Disease2
0.027567148208618